All patients fully engrafted donor cells including five patients with extensive splenomegaly.

A limitation for this approach is the low engraftment of donor cells.

No clinical or radiological adverse effects were directly attributed to the donor cells.

There was no evidence of recurrence of leukemia in donor cells among these patients.

Survival of integrated cells was significantly increased when donor cells were pretreated with AAV-XIAP.

Upon transplantation, the majority of human donor cells could not contribute to myofiber formation.

These contents can influence the function and fate of both recipient and donor cells.

Yet, acquiring donor cells is, in most instances, an invasive procedure that requires laborious isolation.

All recipients treated with anti-CD154 became specifically nonresponsive to donor cells in mixed lymphocyte reactions.

Mice transplanted with 3-day ATRA-treated cells had four-fold more donor cells than the untreated cells.

First, the supply of donor cells is limited, and therefore, surgery is accompanied by difficult logistics.

GFP is frequently used as a marker for tracking donor cells adoptively transplanted into recipient animals.

Preclinical investigations support the concept that donor cells more oriented towards a cardiovascular phenotype favor repair.

Codon-optimized mfat-1 was inserted into eukaryotic expression vectors, which were transferred into primary swine donor cells.

Relative growth kinetics between donor cells on the microcarriers were the same as the monolayer study.

Sites of tissue sparing correlated with the distribution pattern of donor cells in the host brain.